CDK9 and B-cell chronic lymphocytic leukemia: PRT2527: PRT2527 is a selective and potent cyclin-dependent kinase 9 inhibitor that exhibits antiproliferative and proapoptotic activity in DLBCL, CLL, and mantle cell lymphoma (MCL) cell lines [82].